During the past decade, Universidade Federal de São Paulo - Escola Paulista de Medicina conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 10 clinical trials were completed, i.e. on average, 111.1% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 8 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universidade Federal de São Paulo - Escola Paulista de Medicina" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Bayer" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)" with 2 trials sponsored and "GlaxoSmithKline" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universidade Federal de São Paulo - Escola Paulista de Medicina" #1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator, "Bausch Health Americas, Inc." with 1 trials as a collaborator, "Federal University of São Paulo" with 1 trials as a collaborator and "Federal University of Uberlandia" with 1 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 17 trials.

According to Clinical.Site data, the most researched conditions in "Universidade Federal de São Paulo - Escola Paulista de Medicina" are "Autism Spectrum Disorder (ASD)" (2 trials), "Pulmonary Arterial Hypertension" (2 trials), "Retinopathy of Prematurity (ROP)" (2 trials), "Rheumatoid Arthritis" (2 trials) and "Arthritis, Rheumatoid" (1 trials). Many other conditions were trialed in "Universidade Federal de São Paulo - Escola Paulista de Medicina" in a lesser frequency.

Most popular intervention types in "Universidade Federal de São Paulo - Escola Paulista de Medicina" are "Drug" (18 trials), "Procedure" (2 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (5 trials), "Tocilizumab" (3 trials), "Baricitinib" (2 trials), "Eylea (Aflibercept, BAY86-5321)" (2 trials) and "Laser photocoagulation" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universidade Federal de São Paulo - Escola Paulista de Medicina" are 20 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Universidade Federal de São Paulo - Escola Paulista de Medicina". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 17 completed trials in Universidade Federal de São Paulo - Escola Paulista de Medicina, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Universidade Federal de São Paulo - Escola Paulista de Medicina, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".